AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28488911 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-Assisted Lateral Neck Dissection (VALND)
Number of subjects: 64
Study 28488911 — intervention group
Group type: COMPARATOR
Intervention: Open Lateral Neck Dissection (LND)
Number of subjects: 64
Study 26192876 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 (3.2 nmol/kg)
Number of subjects: 60
Study 26192876 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 (6.4 nmol/kg)
Number of subjects: 60
Study 26192876 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 (9.6 nmol/kg)
Number of subjects: 60
Study 26192876 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 (12.8 nmol/kg)
Number of subjects: 60
Study 26192876 — intervention group
Group type: COMPARATOR
Intervention: Control (standard recombinant FSH/GnRH antagonist protocol)
Number of subjects: 60
Study 22336429 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary vitrectomy (PV)
Number of subjects: 0
Study 22336429 — intervention group
Group type: COMPARATOR
Intervention: Scleral buckling surgery (SB)
Number of subjects: 0
Study 21995514 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally focused psychiatric (CFP) consultation including toolkits with psychoeducational booklets, worksheets, and community resources.
Number of subjects: 0
Study 21995514 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study 19204654 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day for 8 weeks, then up to 120 mg/day for 6 months
Number of subjects: 547
Study 19204654 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day for 8 weeks, then up to 20 mg/day for 6 months
Number of subjects: 547
Study 19204654 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 547
Study 19204654 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 547
Study 16766343 — intervention group
Group type: EXPERIMENTAL
Intervention: Coherence judgment task (n = 39)
Number of subjects: 99
Study 16766343 — intervention group
Group type: EXPERIMENTAL
Intervention: Word recognition paradigm (n = 60)
Number of subjects: 99
Study 15611423 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PUVA using methoxsalen capsules and a portable tanning unit at home
Number of subjects: 158
Study 15611423 — intervention group
Group type: COMPARATOR
Intervention: Hospital-administered bath PUVA with trioxsalen
Number of subjects: 158
Study 11452078 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based cases with interactive elements
Number of subjects: 225
Study 11452078 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based cases without interactive elements
Number of subjects: 225
Study 11452078 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based cases with interactive elements
Number of subjects: 225
Study 11452078 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to cases)
Number of subjects: 225
Study 9210005 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 1 g b.i.d.
Number of subjects: 86
Study 9210005 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 1 g t.i.d.
Number of subjects: 86
Study 8223735 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise stress test (CPX)
Number of subjects: 40
Study 8223735 — intervention group
Group type: COMPARATOR
Intervention: Standard ECG exercise stress test (CX)
Number of subjects: 40
Study 8223735 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood lactate kinetics analysis
Number of subjects: 40
Study 30657971 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-collected nasal swab
Number of subjects: 64
Study 30657971 — intervention group
Group type: COMPARATOR
Intervention: Healthcare worker-collected nasopharyngeal swab
Number of subjects: 64
Study 29781558 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (n=218)
Number of subjects: 1777
Study 29781558 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model including clinical variables
Number of subjects: 1777
Study 27795779 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% (1 ml/kg) with fentanyl 1 μg/kg and clonidine 1μg/kg (group I)
Number of subjects: 40
Study 27795779 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 0.25% (1 ml/kg) with fentanyl 1 μg/kg (group II)
Number of subjects: 40
Study 24876164 — intervention group
Group type: EXPERIMENTAL
Intervention: PhotoDyn(®) 750 (PD750), 580‐1400 nm for 30 min
Number of subjects: 88
Study 24876164 — intervention group
Group type: COMPARATOR
Intervention: Waldmann(®) 1200L (Wa1200L), 600‐720 nm for 10‐11 min
Number of subjects: 88
Study 24876164 — intervention group
Group type: EXPERIMENTAL
Intervention: PhotoDyn(®) 750 (PD750)
Number of subjects: 88
Study 24876164 — intervention group
Group type: COMPARATOR
Intervention: Waldmann(®) 1200L (Wa1200L)
Number of subjects: 88
Study 23210419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate whitening dentifrice (Arm & Hammer Advance White Extreme Whitening Baking Soda and Peroxide Toothpaste)
Number of subjects: 146
Study 23210419 — intervention group
Group type: COMPARATOR
Intervention: Negative control dentifrice (silica-based)
Number of subjects: 146
Study 23210419 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued use of whitening dentifrice for an additional two weeks
Number of subjects: 146
Study 23210419 — intervention group
Group type: COMPARATOR
Intervention: Switched to negative control dentifrice for an additional two weeks
Number of subjects: 146
Study 20151972 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg
Number of subjects: 1327
Study 20151972 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg
Number of subjects: 1327
Study 20151972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1327
Study 19224787 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 112
Study 19224787 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine
Number of subjects: 112
Study 16859179 — intervention group
Group type: EXPERIMENTAL
Intervention: Acacia colei seed flour at 25% (w/w)
Number of subjects: 118
Study 16859179 — intervention group
Group type: COMPARATOR
Intervention: All diets (including control)
Number of subjects: 118
Study 12558762 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis treatment
Number of subjects: 123
Study 12558762 — intervention group
Group type: EXPERIMENTAL
Intervention: Beginning of the dialysis program
Number of subjects: 123
Study 10865162 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier-specific telephone counseling (BSTC)
Number of subjects: 1655
Study 10865162 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-based educational intervention (MD-ED)
Number of subjects: 1655
Study 10865162 — intervention group
Group type: COMPARATOR
Intervention: Reminder control (RC)
Number of subjects: 1655
Study 9410299 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (Pulmicort and Horacort) 640 mg or 800 mg daily for 6 weeks
Number of subjects: 55
Study 8408569 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer vaccine (10^6 PFU)
Number of subjects: 302
Study 8408569 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-titer vaccine (10^5 PFU)
Number of subjects: 302
Study 8408569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 3609883 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (5 mg once daily)
Number of subjects: 27
Study 3609883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31353941 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapular exercise programme plus physical therapy treatment
Number of subjects: 102
Study 31353941 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy treatment
Number of subjects: 102
Study 29931835 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (1 Hz, right dorsolateral prefrontal cortex)
Number of subjects: 31
Study 29931835 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 31
Study 29931835 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 31
Study 26704923 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 μg/day Vitamin D3 dissolved in oil
Number of subjects: 94
Study 26704923 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pure oil)
Number of subjects: 94
Study 24878214 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip on Challenging Behavior care program
Number of subjects: 659
Study 24878214 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 659
Study 23328380 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope (G)
Number of subjects: 90
Study 23328380 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscope (F)
Number of subjects: 90
Study 23328380 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of GlideScope and fiberoptic bronchoscope (G+F)
Number of subjects: 90
Study 23328380 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (G, F, G+F)
Number of subjects: 90
Study 19706002 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 131
Study 19706002 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 131
Study 18663331 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly dietetic consultations for 6 months
Number of subjects: 67
Study 18663331 — intervention group
Group type: COMPARATOR
Intervention: Standard care with dietetic consultations every 6 months
Number of subjects: 67
Study 16189970 — intervention group
Group type: EXPERIMENTAL
Intervention: New three-dimensional image processing technique for PET
Number of subjects: 12
Study 11832363 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) injections (n=7)
Number of subjects: 12
Study 11832363 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=5)
Number of subjects: 12
Study 10394114 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented hypokinetic subjects (SHKS) taking daily 23 mg Mg as Mg lactate per kilogram body weight
Number of subjects: 40
Study 10394114 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupplemented hypokinetic subjects (UHKS)
Number of subjects: 40
Study 10394114 — intervention group
Group type: COMPARATOR
Intervention: Supplemented ambulatory control subjects (SACS)
Number of subjects: 40
Study 10394114 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented ambulatory control (UACS)
Number of subjects: 40
Study 10394114 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented hypokinetic subjects (SHKS)
Number of subjects: 40
Study 7574861 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release felodipine
Number of subjects: 21
Study 2344752 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic Treatment Table (KTT)
Number of subjects: 49
Study 2344752 — intervention group
Group type: COMPARATOR
Intervention: Conventional bed care
Number of subjects: 49
Study 6108449 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminoacids (70‐85 g daily in the form of 'Aminosyn' or 'Travasol')
Number of subjects: 35
Study 6108449 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aminoacid therapy)
Number of subjects: 35
Study 31842936 — intervention group
Group type: EXPERIMENTAL
Intervention: FES‐CE‐based intensified rehabilitation
Number of subjects: 150
Study 31842936 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 150
Study 27825914 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Policy
Number of subjects: 0
Study 27825914 — intervention group
Group type: COMPARATOR
Intervention: Standard Policy
Number of subjects: 0
Study 25818925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin
Number of subjects: 0
Study 25818925 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 23652751 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib treatment
Number of subjects: 205
Study 21384391 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-switched Alexandrite laser (50 nanoseconds)
Number of subjects: 20
Study 21384391 — intervention group
Group type: COMPARATOR
Intervention: Long-pulsed Alexandrite laser (100 microseconds)
Number of subjects: 20
Study 19152069 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 32
Study 19152069 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 17288990 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET), 5 sessions
Number of subjects: 18
Study 17288990 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PED), 1 session
Number of subjects: 18
Study 12614412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory phlebectomy
Number of subjects: 82
Study 12614412 — intervention group
Group type: COMPARATOR
Intervention: Compression sclerotherapy
Number of subjects: 82
Study 11093299 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of fast food restaurant use
Number of subjects: 891
Study 11093299 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased frequency of fast food restaurant use over 3 years
Number of subjects: 891
Study 9433650 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral administration of grepafloxacin (200 to 1200 mg)
Number of subjects: 0
Study 9433650 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat oral administration of grepafloxacin (400 and 800 mg)
Number of subjects: 0
Study 9433650 — intervention group
Group type: EXPERIMENTAL
Intervention: Single and repeat doses of grepafloxacin
Number of subjects: 0
Study 9433650 — intervention group
Group type: COMPARATOR
Intervention: Grepafloxacin compared to other quinolones
Number of subjects: 0
Study 8455318 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured triglyceride fat emulsion 73403
Number of subjects: 20
Study 8455318 — intervention group
Group type: COMPARATOR
Intervention: Intralipid 20% (control)
Number of subjects: 20
Study 3460195 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum (2 mg)
Number of subjects: 25
Study 3460195 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 25
Study 3460195 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol-tasting chewing gum
Number of subjects: 25
Study 31482428 — intervention group
Group type: COMPARATOR
Intervention: Model A (clinical)
Number of subjects: 189
Study 31482428 — intervention group
Group type: COMPARATOR
Intervention: Model B (radiomic)
Number of subjects: 189
Study 31482428 — intervention group
Group type: COMPARATOR
Intervention: Model C (radiomic/clinical)
Number of subjects: 189
Study 27933408 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO + PRT (0.33 g/kg body mass of a milk-based protein matrix for 12 weeks)
Number of subjects: 57
Study 27933408 — intervention group
Group type: COMPARATOR
Intervention: PRO (0.33 g/kg body mass of a milk-based protein matrix for 12 weeks)
Number of subjects: 57
Study 25482467 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot condition (26°C)
Number of subjects: 21
Study 25482467 — intervention group
Group type: COMPARATOR
Intervention: Cold condition (19°C)
Number of subjects: 21
Study 23726393 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (haematoma evacuation within 12 hours of randomisation) plus medical treatment
Number of subjects: 601
Study 23726393 — intervention group
Group type: COMPARATOR
Intervention: Initial conservative treatment (medical treatment alone)
Number of subjects: 601
Study 21226674 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy group
Number of subjects: 238
Study 21226674 — intervention group
Group type: COMPARATOR
Intervention: Trained assessor group
Number of subjects: 238
Study 21226674 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental assessment
Number of subjects: 238
Study 19850063 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on the Theory of Planned Behavior (TPB)
Number of subjects: 599
Study 19850063 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 599
Study 16906087 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (transverse partial sacrectomy below S1 neural foramina)
Number of subjects: 10
Study 16906087 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (transverse partial sacrectomy above S1 neural foramina)
Number of subjects: 10
Study 16906087 — intervention group
Group type: COMPARATOR
Intervention: Control Group (sacrum intact)
Number of subjects: 10
Study 15002680 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to substance abuse treatment
Number of subjects: 400
Study 15002680 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to mental health treatment
Number of subjects: 400
Study 15002680 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to substance abuse and mental health treatment
Number of subjects: 400
Study 15002680 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral rates to substance abuse and mental health treatment
Number of subjects: 400
Study 11680554 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition (providing instrumental and emotional support and teaching child management skills to mothers)
Number of subjects: 36
Study 11680554 — intervention group
Group type: COMPARATOR
Intervention: Existing services comparison condition
Number of subjects: 36
Study 9504445 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial risk factor intervention
Number of subjects: 508
Study 9504445 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 508
Study 7999931 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant tones (300 Hz or 6000 Hz)
Number of subjects: 0
Study 7999931 — intervention group
Group type: COMPARATOR
Intervention: Irrelevant tones (300 Hz or 6000 Hz)
Number of subjects: 0
Study 3234475 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic oral solution (12 mg)
Number of subjects: 12
Study 3234475 — intervention group
Group type: COMPARATOR
Intervention: Tablets (12 mg)
Number of subjects: 12
Study 3234475 — intervention group
Group type: COMPARATOR
Intervention: Capsules (12 mg)
Number of subjects: 12
Study 31813531 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1802
Study 31813531 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1802
Study 31813531 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital AF
Number of subjects: 1802
Study 31813531 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge AF
Number of subjects: 1802
Study 31813531 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge AF presence vs absence of in-hospital AF
Number of subjects: 1802
Study 29735974 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal with acupuncture group (n=32)
Number of subjects: 62
Study 29735974 — intervention group
Group type: COMPARATOR
Intervention: Herbal group (n=30)
Number of subjects: 62
Study 28038865 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (6 mg administered ∼24 hours after chemotherapy plus bevacizumab every 14 days for 4 cycles, with the option to continue for ≤ 60 months)
Number of subjects: 845
Study 28038865 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered ∼24 hours after chemotherapy plus bevacizumab every 14 days for 4 cycles, with the option to continue for ≤ 60 months)
Number of subjects: 845
Study 28038865 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Number of subjects: 845
Study 28038865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 845
Study 26167714 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) for abstinence
Number of subjects: 920
Study 26167714 — intervention group
Group type: COMPARATOR
Intervention: Standard care treatment
Number of subjects: 920
Study 23907740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg IV over 1 hour q12h for ABSSSI and CABP patients
Number of subjects: 220
Study 23907740 — intervention group
Group type: COMPARATOR
Intervention: Ceftaroline fosamil 50-2000 mg IV infusion over 1 hour or IM injection q12h or q24h for healthy subjects
Number of subjects: 220
Study 21990808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolytics (IAT)
Number of subjects: 3
Study 19860230 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (2 mg x kg(‐1)) and Suxamethonium (1.2 mg x kg(‐1))
Number of subjects: 10
Study 19860230 — intervention group
Group type: COMPARATOR
Intervention: Propofol (0.75 mg x kg(‐1)) and Suxamethonium (1.2 mg x kg(‐1))
Number of subjects: 10
Study 19860230 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (2 mg x kg(‐1)) and Vecuronium (0.07 mg x kg(‐1))
Number of subjects: 10
Study 19860230 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.75 mg x kg(‐1)) and Vecuronium (0.07 mg x kg(‐1))
Number of subjects: 10
Study 16317061 — intervention group
Group type: EXPERIMENTAL
Intervention: MSH/ACTH(4-10) (0.5 mg) administered intranasally twice daily for 12 weeks
Number of subjects: 23
Study 16317061 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intranasally twice daily for 12 weeks
Number of subjects: 23
Study 15583914 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT measurements of dopamine transporter (DAT) using 123I‐beta‐CIT in IPD patients
Number of subjects: 33
Study 15583914 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT measurements of dopamine transporter (DAT) using 123I‐beta‐CIT in MSA patients
Number of subjects: 33
Study 15583914 — intervention group
Group type: COMPARATOR
Intervention: SPECT measurements of dopamine transporter (DAT) in MSA patients
Number of subjects: 33
Study 15583914 — intervention group
Group type: COMPARATOR
Intervention: SPECT measurements of dopamine transporter (DAT) in IPD patients
Number of subjects: 33
Study 15583914 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT measurements of dopamine D2-like receptors (D2) using 123I‐epidepride in patients
Number of subjects: 33
Study 15583914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio between caudate DAT and D2 binding in IPD patients
Number of subjects: 33
Study 15583914 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT measurements of DAT in patients with reduced striatal 123I‐beta‐CIT binding
Number of subjects: 33